313 related articles for article (PubMed ID: 29987050)
1. Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy.
Xiao T; Li W; Wang X; Xu H; Yang J; Wu Q; Huang Y; Geradts J; Jiang P; Fei T; Chi D; Zang C; Liao Q; Rennhack J; Andrechek E; Li N; Detre S; Dowsett M; Jeselsohn RM; Liu XS; Brown M
Proc Natl Acad Sci U S A; 2018 Jul; 115(31):7869-7878. PubMed ID: 29987050
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.
Yeh WL; Shioda K; Coser KR; Rivizzigno D; McSweeney KR; Shioda T
PLoS One; 2013; 8(4):e60889. PubMed ID: 23593342
[TBL] [Abstract][Full Text] [Related]
3. LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
Schwarz LJ; Fox EM; Balko JM; Garrett JT; Kuba MG; Estrada MV; González-Angulo AM; Mills GB; Red-Brewer M; Mayer IA; Abramson V; Rizzo M; Kelley MC; Meszoely IM; Arteaga CL
J Clin Invest; 2014 Dec; 124(12):5490-502. PubMed ID: 25401474
[TBL] [Abstract][Full Text] [Related]
4. IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer.
Zhang Y; Wester L; He J; Geiger T; Moerkens M; Siddappa R; Helmijr JA; Timmermans MM; Look MP; van Deurzen CHM; Martens JWM; Pont C; de Graauw M; Danen EHJ; Berns EMJJ; Meerman JHN; Jansen MPHM; van de Water B
Oncogene; 2018 Apr; 37(14):1869-1884. PubMed ID: 29353882
[TBL] [Abstract][Full Text] [Related]
5. PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.
Santiago-Gómez A; Kedward T; Simões BM; Dragoni I; NicAmhlaoibh R; Trivier E; Sabin V; Gee JM; Sims AH; Howell SJ; Clarke RB
Cancer Lett; 2019 Aug; 458():66-75. PubMed ID: 31121213
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.
Weigel MT; Ghazoui Z; Dunbier A; Pancholi S; Dowsett M; Martin LA
Breast Cancer Res; 2012 May; 14(3):R78. PubMed ID: 22608253
[TBL] [Abstract][Full Text] [Related]
7. Epigenome-wide SRC-1-Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer.
Ward E; Varešlija D; Charmsaz S; Fagan A; Browne AL; Cosgrove N; Cocchiglia S; Purcell SP; Hudson L; Das S; O'Connor D; O'Halloran PJ; Sims AH; Hill AD; Young LS
Clin Cancer Res; 2018 Aug; 24(15):3692-3703. PubMed ID: 29567811
[No Abstract] [Full Text] [Related]
8. PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER
Truong TH; Benner EA; Hagen KM; Temiz NA; Kerkvliet CP; Wang Y; Cortes-Sanchez E; Yang CH; Trousdell MC; Pengo T; Guillen KP; Welm BE; Dos Santos CO; Telang S; Lange CA; Ostrander JH
Oncogene; 2021 Jun; 40(25):4384-4397. PubMed ID: 34103681
[TBL] [Abstract][Full Text] [Related]
9. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer.
Chu I; Arnaout A; Loiseau S; Sun J; Seth A; McMahon C; Chun K; Hennessy B; Mills GB; Nawaz Z; Slingerland JM
J Clin Invest; 2007 Aug; 117(8):2205-15. PubMed ID: 17627304
[TBL] [Abstract][Full Text] [Related]
10. c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells.
Fan P; Griffith OL; Agboke FA; Anur P; Zou X; McDaniel RE; Creswell K; Kim SH; Katzenellenbogen JA; Gray JW; Jordan VC
Cancer Res; 2013 Jul; 73(14):4510-20. PubMed ID: 23704208
[TBL] [Abstract][Full Text] [Related]
11. SOX9/FXYD3/Src Axis Is Critical for ER
Xue Y; Lai L; Lian W; Tu X; Zhou J; Dong P; Su D; Wang X; Cao X; Chen Y; Wang Q
Mol Cancer Res; 2019 Jan; 17(1):238-249. PubMed ID: 30206184
[TBL] [Abstract][Full Text] [Related]
12. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
Pink JJ; Jordan VC
Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
[TBL] [Abstract][Full Text] [Related]
13. Estrogenic down-regulation of protein tyrosine phosphatase gamma (PTP gamma) in human breast is associated with estrogen receptor alpha.
Liu S; Sugimoto Y; Kulp SK; Jiang J; Chang HL; Park KY; Kashida Y; Lin YC
Anticancer Res; 2002; 22(6C):3917-23. PubMed ID: 12553013
[TBL] [Abstract][Full Text] [Related]
14. Identification of miR-26 as a key mediator of estrogen stimulated cell proliferation by targeting CHD1, GREB1 and KPNA2.
Tan S; Ding K; Li R; Zhang W; Li G; Kong X; Qian P; Lobie PE; Zhu T
Breast Cancer Res; 2014 Apr; 16(2):R40. PubMed ID: 24735615
[TBL] [Abstract][Full Text] [Related]
15. Nuclear and extranuclear pathway inputs in the regulation of global gene expression by estrogen receptors.
Madak-Erdogan Z; Kieser KJ; Kim SH; Komm B; Katzenellenbogen JA; Katzenellenbogen BS
Mol Endocrinol; 2008 Sep; 22(9):2116-27. PubMed ID: 18617595
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer.
Campbell EJ; McDuff E; Tatarov O; Tovey S; Brunton V; Cooke TG; Edwards J
Br J Cancer; 2008 Dec; 99(11):1769-74. PubMed ID: 19018258
[TBL] [Abstract][Full Text] [Related]
17. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
18. Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
Fan P; McDaniel RE; Kim HR; Clagett D; Haddad B; Jordan VC
Eur J Cancer; 2012 Dec; 48(18):3488-98. PubMed ID: 22658320
[TBL] [Abstract][Full Text] [Related]
19. Src Is a Potential Therapeutic Target in Endocrine-Resistant Breast Cancer Exhibiting Low Estrogen Receptor-Mediated Transactivation.
Guest SK; Ribas R; Pancholi S; Nikitorowicz-Buniak J; Simigdala N; Dowsett M; Johnston SR; Martin LA
PLoS One; 2016; 11(6):e0157397. PubMed ID: 27308830
[TBL] [Abstract][Full Text] [Related]
20. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines.
Sikora MJ; Jacobsen BM; Levine K; Chen J; Davidson NE; Lee AV; Alexander CM; Oesterreich S
Breast Cancer Res; 2016 Sep; 18(1):92. PubMed ID: 27650553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
